{
    "id": 22553,
    "fullName": "ABL1 V379I",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 V379I lies within the protein kinase domain of the Abl1 protein (UniProt.org). V379I has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL1 (PMID: 21562040, PMID: 28467002), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3828,
                    "pubMedId": 21562040,
                    "title": "BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21562040"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11531,
                    "pubMedId": 28467002,
                    "title": "The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28467002"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "V379I",
    "createDate": "05/15/2016",
    "updateDate": "10/01/2019",
    "referenceTranscriptCoordinates": {
        "id": 119236,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130874917G>A",
        "cDna": "c.1135G>A",
        "protein": "p.V379I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16834,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 L384M in the context of BCR-ABL1 was identified in a BCR-ABL1-positive chronic myeloid leukemia (CML) with chronic phase CML with hematologic response but no cytogenetic response on Gleevec (imatinib) treatment (PMID: 12204532).",
            "molecularProfile": {
                "id": 23171,
                "profileName": "BCR - ABL1 ABL1 V379I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14949,
                    "pubMedId": 12204532,
                    "title": "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12204532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7977,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations consisted of ABL1 V379I (90%), V379I/H396P (3%), and V379I/H396P (3%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26122,
                "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23168,
            "profileName": "ABL1 V379I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23169,
            "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23170,
            "profileName": "BCR - ABL1 ABL1 V379I ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23171,
            "profileName": "BCR - ABL1 ABL1 V379I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26122,
            "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119236,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130874917G>A",
            "cDna": "c.1135G>A",
            "protein": "p.V379I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}